Long-term follow-up of amlitelimab for moderate to severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial studies the long-term safety and effectiveness of amlitelimab in people with moderate to severe atopic dermatitis (eczema). You may be eligible if you previously joined an amlitelimab eczema study and are continuing into a longer follow-up phase.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old when you sign consent
- You must have previously joined an amlitelimab eczema study and finished the required treatment visits
- You must be at a specific “rollover” time to start this long-term follow-up (or have re-start eligibility after prior safety follow-up)
- Weigh at least 25 kg
- You must be able and willing to follow all study instructions and complete scheduled check-ins
- You must not have certain major health risks, like significant immune system problems, recent organ/stem cell transplant, or active infections such as TB
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
Hear when a new Dermatitis Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.